Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
J Bergh, K Pritchard, S Swain, D Cameron, K Albain, S Anderson, R Arriagada, J Bartlett, E Bergsten-Nordstrom, J Bliss, R Bradley, E Brain, J Braybrooke, L Carey, M Clarke, R Coleman, J Cuzick, N Davidson, L Del Mastro, A Di Leo Show all
LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2021
BACKGROUND: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality. METHODS: We did a collaborative meta-analysis of individual patient data from randomised trials assessing chemotherapy plus trastuzumab versus the same chemotherapy alone. Randomised trials that enrolled women with node-negative or node-positive, operable breast cancer were included. We collected individual patie..View full abstract
Funding Cancer Research UK, UK Medical Research Council.